Neutralizing granzyme b for providing cardioprotection in a subject

The present invention relates to a method for providing cardioprotection in a subject who experienced a myocardial infarction comprising administering […]

A cxcr3b antagonist for the treatment of vitiligo

The present invention relates to a method for treating vitiligo in a subject in need thereof comprising a step of administering to said subject a […]

A pak1/2 inhibitor for the treatment of psoriasis and other nlrp3

The present invention relates to a PAK-1 and/or PAK-2 inhibitor for use in the treatment of NLRP3 inflammasome mediated IL-1beta dependent disorders […]

Methods for the diagnosis and treatment of gastrointestinal stromal

The present invention relates to the diagnosis of gastrointestinal stromal tumors (GISTs). The present invention also relates to methods and […]

A lyn kinase activator for the treatment of braf inhibitor-resistant

The present invention relates to method and composition for treating melanoma. The inventors have shown that a decrease in LYN expression, in melanoma […]

Sphingosine kinase 2 inhibitors in combination with immune checkpoint

Immune checkpoint blockade therapy is based on the inhibition of the tumor-mediated suppression of anticancer immune responses. However, the efficacy […]

Methods and compositions for treating melanoma

The present invention relates to a method and composition for treating melanoma. More particularly, inventors have shown that high expression of USP14 […]

A b cell depleting agent for the treatment of atherosclerosis or post

New anti-atherogenic strategies based on B cell modulation, and suggest that patients currently treated with CD20 antibodies for other immune-mediated […]

Antagonists of il-33 for use in methods for preventing ischemia

Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, […]

Ngal as a novel target for the treatment of chronic kidney disease

The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, […]